General “News” category

Welcome to Belong, a New Online Cancer Community

2019-08-22T13:59:06-05:00August 21st, 2019|Hot Topics, News|

GO2 Foundation has partnered with Belong.Life to provide patient and caregiver support and education on the world’s largest social network for cancer patients. Within the GO2 Foundation membership area, our social workers, clinical trial specialists, and survivor-volunteers will provide hope, education, and support for those living with lung cancer. Members will get the latest treatment updates, access to GO2 Foundation’s suite of educational materials, an appointment tracker, an area to store medical documents, and peer-to-peer support. "The Belong app, to me, [...]

FDA Approves Genentech’s Rozlytrek (entrectinib) for ROS1 Non-Small Cell Lung Cancer (NSCLC) and NTRK-Driven Tumors

2019-08-16T10:54:48-05:00August 16th, 2019|Hot Topics, News|

On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor that is NTRK fusion-positive, following progression on other therapies. This approval offers a new targeted therapy option for patients with both of these rare mutations and is only the third time that the FDA has approved a targeted therapy for any [...]

GO2 Foundation Presents 2019 Bonnie J. Addario Lectureship Award at ILCC

2019-08-15T10:46:56-05:00August 2nd, 2019|Hot Topics, News|

GO2 Foundation for Lung Cancer is pleased to announce that it presented Solange Peters, MD, PhD, with the 2019 Bonnie J. Addario Lectureship Award for her emphasis on groundbreaking biomarker research, improving access to care for lung cancer patients worldwide, and supporting the advancement of women in oncology. GO2 Foundation honored Prof. Peters with the award at the International Lung Cancer Conference (ILCC) held July 25-27 in Huntington Beach, California. Read more.

An Update on the Burn Pits Accountability Act of 2019

2019-07-17T10:10:20-05:00July 17th, 2019|Hot Topics, News|

Click here to read our statement in support of the legislation. GO2 Foundation for Lung Cancer is pleased to report the recent advancement of the Burn Pits Accountability Act. We strongly support this legislation as a first step to ensure that all those affected by burn pit toxins are accounted for, in order to call for further research focused on these veterans. Since the Persian Gulf War, a common waste disposal practice at military sites outside the United States was [...]

Make an Impact from Home, 7/23!

2019-08-15T10:45:57-05:00July 16th, 2019|News|

On July 23, over 130 advocates will meet with elected officials on Capitol Hill to advocate for the lung cancer community at the GO2 Foundation National Advocacy Summit. Now you have the opportunity to strengthen the collective voice and ignite change—without leaving your home! Join us on July 23 for Virtual Advocacy Action Day, an opportunity for you to echo the voices of advocates in Washington from wherever you are. We’ve made getting involved easy with pre-written tweets and emails, [...]

New Treatment Approved for Metastatic Small Cell Lung Cancer

2019-06-18T21:12:11-05:00June 18th, 2019|Hot Topics, News|

On June 17, 2019, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Though pembrolizumab is an established treatment option for non-small cell lung cancer, this is the first approval of pembrolizumab for small cell lung cancer. This approval was based on two clinical trials, KEYNOTE-158 and KEYNOTE-028, which measured tumor [...]

Early Screening Equals Early Diagnosis

2019-06-24T11:18:16-05:00June 18th, 2019|Hot Topics, News|

GO2 Foundation for Lung Cancer’s recently published scientific paper found that lung cancer screening programs can successfully detect lung cancer early with the majority of lung cancers diagnosed at stage 1 or limited stage. Importantly, outcomes at academic and nonacademic sites were compared and the data confirmed that responsible screening can take place in a community setting. Figure B: Percentage of each stage and type of lung cancer diagnosed at nonacademic centers compared with academic centers. Published in [...]

Lung Cancer News from the Largest Oncology Meeting

2019-06-17T12:07:14-05:00June 13th, 2019|Hot Topics, News|

The GO2 Science and Research team just returned from the 2019 American Society of Clinical Oncology (ASCO) meeting. We connect you and your loved ones to the latest research and treatment options by keeping up with the latest advances at meetings like ASCO. While there we saw exciting presentations on new research advances and potential new treatment options for lung cancer patients. Below are some key takeaways: Targeted Therapy Key Takeaway: All patients should receive comprehensive molecular testing/biomarker testing because [...]